Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy

Jin Hu; Jianquan Shi; Yeshuang Yuan; Shengjie Li; Bo Zhang; Haitao Dong; Qing Zhong; Qiu Xie; Xiaoyin Bai; Yingxing Li

doi:10.1039/d2ra04978c

Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy

RSC Adv. 2022 Oct 4;12(43):28279-28282. doi: 10.1039/d2ra04978c. eCollection 2022 Sep 28.

Authors

Jin Hu¹, Jianquan Shi², Yeshuang Yuan³, Shengjie Li¹, Bo Zhang¹, Haitao Dong⁴, Qing Zhong¹, Qiu Xie¹, Xiaoyin Bai⁵, Yingxing Li¹

Affiliations

¹ Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing 100730 China [email protected].
² Department of Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing 101149 China.
³ Department of Rheumatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Clinical Immunology Center, Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing 100730 China.
⁴ Department of Stomatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing 100730 China.
⁵ Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College Beijing 100730 China.

Abstract

We report an easy but universal protein modification approach, self-fused concatenation (SEC), to biosynthesize a set of interferon (IFN) concatemers with improved in vitro bioactivity, in vivo pharmacokinetics and therapeutic efficacy over the monomeric IFN, and the results can be positively enhanced by the concatenated number of self-fused proteins.